|Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?|
|PMID: 23328895 Owner: NLM Status: MEDLINE|
|There is increasing evidence that pregnancy alters the function of drug-metabolizing enzymes and drug transporters in a gestational-stage and tissue-specific manner. In vivo probe studies have shown that the activity of several hepatic cytochrome P450 enzymes, such as CYP2D6 and CYP3A4, is increased during pregnancy, whereas the activity of others, such as CYP1A2, is decreased. The activity of some renal transporters, including organic cation transporter and P-glycoprotein, also appears to be increased during pregnancy. Although much has been learned, significant gaps still exist in our understanding of the spectrum of drug metabolism and transport genes affected, gestational age-dependent changes in the activity of encoded drug metabolizing and transporting processes, and the mechanisms of pregnancy-induced alterations. In this issue of Drug Metabolism and Disposition, a series of articles is presented that address the predictability, mechanisms, and magnitude of changes in drug metabolism and transport processes during pregnancy. The articles highlight state-of-the-art approaches to studying mechanisms of changes in drug disposition during pregnancy, and illustrate the use and integration of data from in vitro models, animal studies, and human clinical studies. The findings presented show the complex inter-relationships between multiple regulators of drug metabolism and transport genes, such as estrogens, progesterone, and growth hormone, and their effects on enzyme and transporter expression in different tissues. The studies provide the impetus for a mechanism- and evidence-based approach to optimally managing drug therapies during pregnancy and improving treatment outcomes.|
|Nina Isoherranen; Kenneth E Thummel|
Related Documents :
|10416965 - Sp1 in pregnancies with down syndrome in the first trimester of pregnancy. internationa...
24192125 - Pregnancy and pharmacogenomics in the context of drug metabolism and response.
24686805 - Methylmalonic acidaemia in pregnancy.
15042005 - An outcomes analysis of five prenatal screening strategies for trisomy 21 in women youn...
2314775 - Mosaicism in chorionic villus sampling: an association with poor perinatal outcome.
1290145 - Growth of the human metatarsal bones in the fetal period (13-24 weeks postconception): ...
|Type: Comment; Journal Article; Research Support, N.I.H., Extramural|
|Title: Drug metabolism and disposition: the biological fate of chemicals Volume: 41 ISSN: 1521-009X ISO Abbreviation: Drug Metab. Dispos. Publication Date: 2013 Feb|
|Created Date: 2013-01-18 Completed Date: 2013-07-12 Revised Date: 2014-02-04|
Medline Journal Info:
|Nlm Unique ID: 9421550 Medline TA: Drug Metab Dispos Country: United States|
|Languages: eng Pagination: 256-62 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
ATP-Binding Cassette Transporters
Adrenal Glands / enzymology*
Aryldialkylphosphatase / metabolism*
Carboxylesterase / metabolism*
Cholestasis / metabolism*
Cotinine / metabolism*
Cytochrome P-450 Enzyme System / biosynthesis, genetics, metabolism*
Estradiol / pharmacology*
Estrogen Receptor alpha / agonists*
Estrogens / pharmacology*
Ethinyl Estradiol / pharmacology*
Fetus / drug effects*
Gene Expression Regulation, Developmental / drug effects*
Glucuronosyltransferase / genetics, metabolism*
Hepatocytes / drug effects*, metabolism*
Hydroxyprogesterones / metabolism*
Intestine, Small / enzymology*
Kidney / enzymology*, metabolism*
Liver / drug effects*, enzymology*
Lung / enzymology*
Membrane Transport Proteins / metabolism*
Multidrug Resistance-Associated Proteins / drug effects*
Organic Anion Transporters / metabolism*
Pesticides / metabolism*
Placenta / drug effects*, enzymology*
Progesterone / pharmacology*
RNA, Messenger / biosynthesis*
Smoking / adverse effects*
Taurocholic Acid / metabolism*
|U10HD047892/HD/NICHD NIH HHS|
|0/Estrogen Receptor alpha; 0/Estrogens; 0/Hydroxyprogesterones; 0/Membrane Transport Proteins; 0/Multidrug Resistance-Associated Proteins; 0/Organic Anion Transporters; 0/Pesticides; 0/RNA, Messenger; 0/multidrug resistance-associated protein 3; 423D2T571U/Ethinyl Estradiol; 4G7DS2Q64Y/Progesterone; 4TI98Z838E/Estradiol; 5E090O0G3Z/Taurocholic Acid; 630-56-8/17-alpha-hydroxy-progesterone caproate; 9035-51-2/Cytochrome P-450 Enzyme System; EC 220.127.116.11/retinoic acid 4-hydroxylase; EC 2.4.1.-/UGT2B7 protein, human; EC 18.104.22.168/Glucuronosyltransferase; EC 22.214.171.124/UDP-glucuronosyltransferase 2B15, human; EC 126.96.36.199/UGT2B17 protein, human; EC 188.8.131.52/Carboxylesterase; EC 184.108.40.206/Aryldialkylphosphatase; EC 220.127.116.11/PON1 protein, mouse; K5161X06LL/Cotinine|
Drug Metab Dispos. 2013 Feb;41(2):263-9
Drug Metab Dispos. 2013 Feb;41(2):320-5 [PMID: 22896729 ]
Drug Metab Dispos. 2013 Feb;41(2):275-80 [PMID: 23077105 ]
Drug Metab Dispos. 2013 Feb;41(2):296-304 [PMID: 23129211 ]
Drug Metab Dispos. 2013 Feb;41(2):326-31 [PMID: 23223497 ]
Drug Metab Dispos. 2013 Feb;41(2):332-42 [PMID: 23175668 ]
Drug Metab Dispos. 2013 Feb;41(2):305-11 [PMID: 23209192 ]
Drug Metab Dispos. 2013 Feb;41(2):291-5 [PMID: 23223495 ]
Drug Metab Dispos. 2013 Feb;41(2):312-9 [PMID: 23150428 ]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Monitoring Programme on Toxic Metal in Bluefish (Pomatomus saltatrix), Anchovy (Engraulis encrasicol...
Next Document: The interacting MYB75 and KNAT7 transcription factors modulate secondary cell wall deposition both i...